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Clinical PerspectiveWhat Is New?This is the first study to examine the association of inappropriate left ventricular mass with cardiovascular disease events and mortality among a cohort of blacks.The prevalence of inappropriate left ventricular mass among blacks is 13.8%.In adjusted analyses, inappropriate left ventricular mass was associated with an increased risk of cardiovascular disease events but not mortality.What Are the Clinical Implications?By accounting for multiple characteristics, including cardiac workload, sex, and body size, inappropriate left ventricular mass may provide an individualized approach to identify blacks at increased cardiovascular risk.

Introduction {#jah34361-sec-0008}
============

Alterations in left ventricular mass (LVM) can be affected by an individual\'s sex, body size, and cardiac workload.[1](#jah34361-bib-0001){ref-type="ref"}, [2](#jah34361-bib-0002){ref-type="ref"}, [3](#jah34361-bib-0003){ref-type="ref"} There is considerable interindividual variability in the extent to which LVM is affected by increased cardiac workload. Left ventricular hypertrophy (LVH), defined as LVM above a prespecified population‐derived threshold, is considered a pathological response to increased blood pressure (BP) and cardiac workload and is associated with an increased risk for cardiovascular disease (CVD) events and mortality.[4](#jah34361-bib-0004){ref-type="ref"}, [5](#jah34361-bib-0005){ref-type="ref"}, [6](#jah34361-bib-0006){ref-type="ref"} However, LVH, defined using population‐derived thresholds, does not correctly identify pathological increases in LVM for all individuals, especially when body composition is altered or in different racial/ethnic groups.[7](#jah34361-bib-0007){ref-type="ref"} Furthermore, an increase in LVM above a prespecified threshold is not always pathological as there are certain normal physiological states (ie, pregnancy or athlete\'s heart) where an increase in LVM represents an "appropriate" and compensatory response to increased cardiac workload and is not associated with increased cardiovascular risk.[1](#jah34361-bib-0001){ref-type="ref"}, [2](#jah34361-bib-0002){ref-type="ref"}, [3](#jah34361-bib-0003){ref-type="ref"} Therefore, approaches to distinguish between compensatory increases in LVM and pathological changes may provide additional information on CVD risk.

An approach that may better characterize the response to increased cardiac workload than consideration of LVM above a certain prespecified threshold is the observed/predicted LVM ratio.[8](#jah34361-bib-0008){ref-type="ref"}, [9](#jah34361-bib-0009){ref-type="ref"} The term "inappropriate" LVM (iLVM) refers to an elevated observed/predicted LVM ratio and is used to characterize the presence of LVM that exceeds a predicted value that is based on an individual\'s sex, body size, and cardiac workload.[9](#jah34361-bib-0009){ref-type="ref"} There are few published data on the prevalence of, and factors associated with, iLVM or its prognostic significance among blacks, a group who is at high risk for CVD events and mortality compared with other racial/ethnic groups in the United States.[10](#jah34361-bib-0010){ref-type="ref"}, [11](#jah34361-bib-0011){ref-type="ref"} We determined the association of iLVM with CVD events and, secondarily, all‐cause mortality among participants in the JHS (Jackson Heart Study), a community‐based cohort study composed exclusively of blacks.

Methods {#jah34361-sec-0009}
=======

Study Population {#jah34361-sec-0010}
----------------

The data that support the findings of this study are available from the corresponding author on reasonable request. The JHS is a community‐based prospective cohort study designed to evaluate CVD risk among blacks.[12](#jah34361-bib-0012){ref-type="ref"} The JHS enrolled 5306 noninstitutionalized blacks, aged ≥21 years, from the ARIC (Atherosclerosis Risk in Communities) study site in Jackson, MS, a representative sample of urban and rural Jackson metropolitan tricounty (Hinds, Madison, and Rankin Counties) residents, volunteers, randomly contacted individuals, and secondary family members of participants.[13](#jah34361-bib-0013){ref-type="ref"}

Participants were excluded from the current analysis if they had incomplete echocardiographic data (n=276) or missing data (ie, age, sex, height, and weight) required to calculate observed and predicted LVM (n=11). Because the predicted LVM equation was developed among adults aged \<85 years,[9](#jah34361-bib-0009){ref-type="ref"} participants aged \>85 years (n=14) were excluded. Participants with a history of myocardial infarction or stroke (n=427) at baseline were excluded. As described below, consistent with prior studies,[14](#jah34361-bib-0014){ref-type="ref"}, [15](#jah34361-bib-0015){ref-type="ref"} participants with an observed/predicted LVM ratio below the fifth percentile (n=151) were considered to have "low" LVM and were excluded from the current study. Finally, participants with an observed/predicted LVM ratio \>400% (n=3) were excluded for physiologic implausibility, leaving a final sample size of 4424 participants for all analyses.

The JHS protocol and all data collection procedures were approved by the Institutional Review Boards of University of Mississippi Medical Center, Jackson State University, and Tougaloo College. All study participants provided written informed consent. The current analysis was approved by the Institutional Review Board at Columbia University and University of Alabama at Birmingham.

Study Procedures {#jah34361-sec-0011}
----------------

At the baseline study visit in 2000 to 2004, participants completed interviewer and self‐administered questionnaires and an examination that included blood and urine collection and 2‐dimensional echocardiography. Detailed descriptions of data collection, methods, and processing have been described previously[13](#jah34361-bib-0013){ref-type="ref"} and are available in [Data S1](#jah34361-sup-0001){ref-type="supplementary-material"}. During the baseline in‐home interview, trained staff administered questionnaires to collect self‐reported information on demographics, health behaviors (eg, alcohol consumption, current smoking, and physical activity), and previously diagnosed comorbid conditions. Antihypertensive medication use was defined by self‐report. A standardized protocol was followed to measure BP.[16](#jah34361-bib-0016){ref-type="ref"}, [17](#jah34361-bib-0017){ref-type="ref"} Prevalent hypertension was defined as a systolic BP (SBP) ≥140 mm Hg, a diastolic BP (DBP) ≥90 mm Hg, or antihypertensive medication use. Estimated glomerular filtration rate (eGFR) was calculated using the Chronic Kidney Disease Epidemiology Collaboration equation.[18](#jah34361-bib-0018){ref-type="ref"} Reduced eGFR was defined as levels \<60 mL/min per 1.73 m^2^.[18](#jah34361-bib-0018){ref-type="ref"}

Echocardiography {#jah34361-sec-0012}
----------------

Certified technicians performed 2‐dimensional transthoracic echocardiograms (Sonos‐4500; Philips Medical Systems) using standardized protocols.[19](#jah34361-bib-0019){ref-type="ref"} Clinical interpretations and analytical measurements of the echocardiograms were performed by experienced cardiologists (DA, MA) on networked image workstations (Vericis; Camtronics Medical Systems).[19](#jah34361-bib-0019){ref-type="ref"} Left ventricular dimensions, including left ventricular internal diameter in diastole (LVIDd; millimeters), left ventricular internal diameter in systole (LVIDs; millimeters), interventricular septal thickness in diastole (IVSd; millimeters), and posterior wall thickness in diastole (PWTd; millimeters), were assessed according to 2015 American Society of Echocardiography and European Association of Cardiovascular Imaging recommendations and used to calculate LVM, LVM index (LVMI), and LVH.[20](#jah34361-bib-0020){ref-type="ref"}

Relative wall thickness (RWT) was calculated using the American Society of Echocardiography formula: RWT=(2×PWTd)/LVIDd.[21](#jah34361-bib-0021){ref-type="ref"} Normal RWT was defined as RWT ≤0.42, and increased RWT was defined as RWT \>0.42.[21](#jah34361-bib-0021){ref-type="ref"} Patterns of left ventricular structure were defined as follows: normal (normal LVMI and normal RWT); concentric remodeling (normal LVMI and increased RWT); eccentric hypertrophy (LVH and normal RWT); and concentric hypertrophy (LVH and increased RWT).[21](#jah34361-bib-0021){ref-type="ref"}, [22](#jah34361-bib-0022){ref-type="ref"} Fractional shortening was defined as follows: \[(LVIDd--LVIDs)/(LVIDd)\]×100%. Left ventricular ejection fraction was derived semiquantitatively (to nearest 5%).[23](#jah34361-bib-0023){ref-type="ref"}

LVM was calculated using the 2015 American Society of Echocardiography/European Association of Cardiovascular Imaging formula: 0.8×{1.04×\[(IVSd+LVIDd+PWTD)^3^−(LVIDd)^3^\]}+0.6.[20](#jah34361-bib-0020){ref-type="ref"} LVMI was calculated as LVM indexed to height^2.7^, and LVH was defined as LVMI ≥45 g/m^2.7^ in women and ≥49 g/m^2.7^ in men.[21](#jah34361-bib-0021){ref-type="ref"}, [24](#jah34361-bib-0024){ref-type="ref"} As previously described, stroke work was calculated as follows: (SBP×stroke volume)×0.0144.[25](#jah34361-bib-0025){ref-type="ref"} Stroke volume was defined as left ventricular end‐diastolic volume minus left ventricular end‐systolic volume, determined using the Teichholz formula: Volume=\[7.0/(2.4+D)\]×D^3^, where D=LVIDd and LVIDs, respectively.[25](#jah34361-bib-0025){ref-type="ref"} Predicted LVM was calculated for each participant as follows: 55.37+\[(6.64×height^2.7^)+(0.64×stroke work)\]--(18.07×sex), where sex=1 for men and 2 for women.[9](#jah34361-bib-0009){ref-type="ref"} The observed/predicted LVM ratio was calculated as 100×(observed LVM/predicted LVM). This ratio was first estimated in a healthy reference population of JHS participants at the baseline visit. The healthy population was defined as JHS participants who were free from hypertension, were free from diabetes mellitus, and had a body mass index \<30 kg/m^2^ (n=892). This population was then used to identify the 5th and 95th percentiles in the observed/predicted LVM distribution (71.6% and 128.2%, respectively). Participants with an observed/predicted ratio \>128.2% were categorized as having iLVM, whereas those with an observed/predicted ratio between 71.6% and 128.2% were categorized as having "appropriate" LVM (aLVM).

Outcomes {#jah34361-sec-0013}
--------

The primary outcome was a composite of CVD events (definite or probable nonfatal myocardial infarction, fatal coronary heart disease, or stroke, defined as noncarotid embolic or thrombotic brain infarction, brain hemorrhage, or subarachnoid hemorrhage).[26](#jah34361-bib-0026){ref-type="ref"} All‐cause mortality was examined as a secondary outcome. A detailed description of event adjudication and follow‐up procedures have been described previously and are available in [Data S1](#jah34361-sup-0001){ref-type="supplementary-material"}.[26](#jah34361-bib-0026){ref-type="ref"} CVD events and all‐cause mortality were available through December 31, 2012.

Statistical Analysis {#jah34361-sec-0014}
--------------------

Participant characteristics were calculated for the study population, overall, and for participants with iLVM and aLVM, separately. Characteristics of participants with iLVM and aLVM were also calculated stratified by LVH status. To account for participants with missing data for covariates (n=484; [Table S1](#jah34361-sup-0001){ref-type="supplementary-material"}), multiple imputation was performed using chained equations and 10 data sets.[27](#jah34361-bib-0027){ref-type="ref"}

The cumulative incidence of CVD events was calculated for participants with iLVM and aLVM using the Kaplan‐Meier method. CVD incidence rates were calculated for participants with iLVM and aLVM, separately. Using Cox proportional hazards regression, the hazard ratios (HRs) and 95% CIs for CVD events associated with iLVM versus aLVM were calculated in nested models with progressive adjustment. Model 1 included adjustment for age, sex, and body mass index. Model 2 included the variables in model 1 and education, current smoking, alcohol use, physical activity, diabetes mellitus, and reduced eGFR. Model 3 included the variables in model 2 and SBP, DBP, and antihypertensive medication use. Model 4 included the variables in model 3 and LVH. Subgroup analyses were conducted by calculating CVD incidence rates and HRs associated with iLVM versus aLVM among participants with and without LVH, separately. Tests for interaction between iLVM and LVH for CVD events were calculated in models including the full population, main effect terms, and a multiplicative interaction term (ie, iLVM×LVH). Adjusted HRs (95% CIs) for CVD events were calculated for each SD higher observed/predicted LVM ratio for all models in the overall cohort and after stratifying by LVH status. The above analyses were repeated using all‐cause mortality as the outcome. *P*\<0.05 was considered statistically significant. All data analyses were conducted using SAS, version 9.4 (SAS Institute, Cary, NC), or Stata/IC, version 12.1 (Stata Inc, College Station, TX).

Results {#jah34361-sec-0015}
=======

Participant Characteristics {#jah34361-sec-0016}
---------------------------

Overall, 13.8% of participants had iLVM and 14.0% had LVH (Table [1](#jah34361-tbl-0001){ref-type="table"}). Compared with participants with aLVM, those with iLVM were older, were more likely to be women, to have less than a high school education, to have diabetes mellitus, to have reduced eGFR, and to have prevalent hypertension, and were more likely to be taking antihypertensive medication. Also, participants with iLVM had a higher mean body mass index, a higher pulse pressure, and a lower DBP. Compared with their counterparts who had aLVM, participants with iLVM had a higher LVMI and a higher prevalence of LVH. Participants with iLVM had a higher prevalence of reduced ejection fraction, eccentric hypertrophy, and concentric hypertrophy. Other echocardiographic parameters for participants with aLVM and iLVM are shown in [Table S2](#jah34361-sup-0001){ref-type="supplementary-material"}. iLVM was present in 6.5% of participants without LVH and 58.5% of participants with LVH. Characteristics of participants with aLVM and iLVM by LVH status are shown in [Table S3](#jah34361-sup-0001){ref-type="supplementary-material"}.

###### 

Characteristics of the JHS Participants With aLVM and iLVM

  Characteristics                                 Overall Sample (n=4424)   aLVM (n=3815)    iLVM (n=609)     *P* Value[a](#jah34361-note-0003){ref-type="fn"}
  ----------------------------------------------- ------------------------- ---------------- ---------------- --------------------------------------------------
  Age, mean (SD), y                               54.48 (12.66)             53.91 (12.65)    58.08 (12.10)    \<0.001
  Women, %                                        64.94                     64.35            68.64            0.040
  Body mass index, mean (SD), kg/m^2^             31.92 (7.22)              31.48 (7.00)     34.66 (7.97)     \<0.001
  Education less than high school, %              17.97                     17.08            23.52            \<0.001
  Current smoking, %                              12.05                     11.90            12.97            0.451
  Physical activity category, %                                                                               
  Ideal                                           47.79                     46.80            54.02            0.002
  Intermediate                                    32.28                     32.63            30.05            
  Poor                                            19.93                     20.57            15.93            
  Alcohol use, %                                                                                              
  Nondrinker                                      63.90                     62.67            71.59            \<0.001
  Moderate drinker                                32.75                     33.66            27.09            
  Heavy drinker                                   3.35                      3.67             1.31             
  Diabetes mellitus, %                            20.57                     18.89            31.07            \<0.001
  eGFR \<60 mL/min per m^2^, %                    7.60                      6.55             14.12            \<0.001
  HDL cholesterol, mean (SD), mg/dL               51.94 (14.56)             52.05 (14.58)    51.25 (14.39)    0.239
  Total cholesterol, mean (SD), mg/dL             199.70 (39.79)            199.70 (39.32)   199.90 (42.74)   0.905
  SBP, mean (SD), mm Hg                           126.62 (16.32)            126.60 (15.96)   127.00 (18.40)   0.574
  DBP, mean (SD), mm Hg                           75.75 (8.62)              75.92 (8.39)     74.68 (9.89)     0.003
  Pulse pressure, mean (SD), mm Hg                50.88 (14.05)             50.64 (13.90)    52.33 (14.84)    0.009
  Prevalent hypertension, %                       54.34                     51.79            70.58            \<0.001
  No. of antihypertensive medication classes, %                                                               
  0                                               52.12                     54.78            35.47            \<0.001
  1                                               18.74                     18.53            20.03            
  2                                               18.58                     17.27            26.77            
  3                                               10.56                     9.41             17.73            
  Antihypertensive medication use, %              47.42                     44.62            65.31            \<0.001
  LVM, mean (SD), g                               149.04 (42.33)            140.00 (32.04)   205.90 (53.37)   \<0.001
  LVMI, mean (SD), g/m^2.7^                       36.37 (10.21)             34.05 (7.61)     50.88 (12.27)    \<0.001
  LVH, %                                          13.95                     6.71             59.28            \<0.001
  Ejection fraction, mean (SD), %                 61.91 (7.26)              62.16 (6.85)     60.34 (9.25)     \<0.001
  Ejection fraction ≤40%, %                       0.66                      0.26             3.15             \<0.001
  Eccentric hypertrophy, %                        8.34                      5.58             25.62            \<0.001
  Concentric hypertrophy, %                       5.61                      1.13             33.66            \<0.001

LVH is defined as LVMI ≥45 g/m^2.7^ in women and ≥49 g/m^2.7^ in men. LVMI is calculated as LVM/height^2.7^. Relative wall thickness (RWT) was calculated using the American Society of Echocardiography formula: RWT=2×(posterior wall thickness in diastole/left ventricular internal dimension in diastole). Increased RWT is defined as RWT \>0.42. Normal RWT is defined as RWT ≤0.42. Eccentric hypertrophy is defined as follows: LVH and normal RWT. Concentric hypertrophy is defined as follows: LVH and increased RWT. aLVM indicates appropriate LVM; DBP, diastolic blood pressure; eGFR, estimated glomerular filtration rate; HDL, high‐density lipoprotein; iLVM, inappropriate LVM; JHS, Jackson Heart Study; LVH, left ventricular hypertrophy; LVM, left ventricular mass; LVMI, LVM index; SBP, systolic blood pressure.

*P* value comparing participants with aLVM and iLVM.

iLVM and Risk of CVD Events {#jah34361-sec-0017}
---------------------------

Over a median follow‐up of 9.7 years (maximum, 12.3 years), there were 262 CVD events (182 among participants with aLVM and 80 among those with iLVM). The cumulative incidence and incidence rates of CVD events were higher for participants with iLVM versus aLVM (Figure [1](#jah34361-fig-0001){ref-type="fig"} and Table [2](#jah34361-tbl-0002){ref-type="table"}). After each level of adjustment, including a model with adjustment for LVH, iLVM was associated with an increased HR for CVD. Among participants with and without LVH, the incidence rates of CVD events were higher for those with iLVM compared with aLVM. Higher observed/predicted LVM ratio, modeled as a continuous variable, was associated with an increased risk of CVD events overall and among participants with and without LVH after multivariable adjustment ([Table S4](#jah34361-sup-0001){ref-type="supplementary-material"}).

![Cumulative incidence of cardiovascular disease (CVD) events associated with appropriate left ventricular mass (aLVM) and inappropriate left ventricular mass (iLVM). Cumulative incidence of CVD events among participants with aLVM (solid line) and iLVM (dashed line) in the overall analytic sample.](JAH3-8-e011897-g001){#jah34361-fig-0001}

###### 

Incidence Rates and HRs for CVD Events Associated With iLVM Versus aLVM in the Overall Analytic Sample and Among Participants Without and With LVH

  Variable               CVD Events/No. at Risk   Incidence Rate (95% CI)[a](#jah34361-note-0005){ref-type="fn"}   HR (95% CI)                                                 
  ---------------------- ------------------------ ---------------------------------------------------------------- ------------------- ------------------- ------------------- -----------------------------------------
  Overall (N=4424)                                                                                                                                                             
  aLVM                   182/3815                 5.34 (4.62--6.18)                                                1 (Reference)       1 (Reference)       1 (Reference)       1 (Reference)
  iLVM                   80/609                   15.40 (12.37--19.17)                                             2.53 (1.93--3.31)   2.14 (1.63--2.80)   2.08 (1.59--2.74)   1.87 (1.33--2.62)
  Without LVH (N=3807)                                                                                                                                                         
  aLVM                   155/3559                 4.86 (4.16--5.69)                                                1 (Reference)       1 (Reference)       1 (Reference)       [b](#jah34361-note-0006){ref-type="fn"}
  iLVM                   29/248                   13.45 (9.35--19.36)                                              2.72 (1.82--4.06)   2.31 (1.54--3.46)   2.53 (1.68--3.81)   [b](#jah34361-note-0006){ref-type="fn"}
  With LVH (N=617)                                                                                                                                                             
  aLVM                   27/256                   12.36 (8.48--18.02)                                              1 (Reference)       1 (Reference)       1 (Reference)       [b](#jah34361-note-0006){ref-type="fn"}
  iLVM                   51/361                   16.77 (12.75--22.07)                                             1.29 (0.81--2.08)   1.05 (0.65--1.70)   1.21 (0.74--2.00)   [b](#jah34361-note-0006){ref-type="fn"}

Model 1: adjusted for age, sex, and body mass index. Model 2: adjusted for the variables in model 1 and diabetes mellitus, estimated glomerular filtration rate \<60 mL/min per 1.73 m^2^, education level (less than high school), current smoking, physical activity, and alcohol use (none, moderate, or heavy). Model 3: adjusted for the variables in model 2 and systolic blood pressure, diastolic blood pressure, and antihypertensive medication use. Model 4: adjusted for the variables in model 3 and LVH. The test for interaction between LVH and iLVM for CVD events had a *P* ~interaction~=0.029 (on model 4). aLVM indicates appropriate left ventricular mass; CVD, cardiovascular disease; HR, hazard ratio; iLVM, inappropriate left ventricular mass; LVH, left ventricular hypertrophy.

Incidence rate per 1000 person‐years (95% CI).

Model 4 was not performed as these analyses are stratified by LVH status.

iLVM and Risk of All‐Cause Mortality {#jah34361-sec-0018}
------------------------------------

Over a median follow‐up of 9.8 years (maximum, 12.3 years), there were 419 deaths (309 and 110 among participants with aLVM and iLVM, respectively). Cumulative mortality was higher among participants with iLVM compared with their counterparts with aLVM (Figure [2](#jah34361-fig-0002){ref-type="fig"} and Table [3](#jah34361-tbl-0003){ref-type="table"}). After multivariable adjustment, including for LVH, the HR for all‐cause mortality comparing participants with iLVM versus aLVM was 1.29 (95% CI, 0.98--1.70). After multivariable adjustment, higher observed/predicted LVM ratio, modeled as a continuous variable, was associated with an increased risk of all‐cause mortality in the overall cohort and among participants with LVH ([Table S5](#jah34361-sup-0001){ref-type="supplementary-material"}).

![Cumulative all‐cause mortality associated with appropriate left ventricular mass (aLVM) and inappropriate left ventricular mass (iLVM). Cumulative all‐cause mortality among participants with aLVM (solid line) and iLVM (dashed line) in the overall analytic sample.](JAH3-8-e011897-g002){#jah34361-fig-0002}

###### 

Mortality Rates and HRs for All‐Cause Mortality Associated With iLVM Versus aLVM in the Overall Analytic Sample and Among Participants Without and With LVH

  Variable               Deaths/No. at Risk   Mortality Rate (95% CI)[a](#jah34361-note-0008){ref-type="fn"}   HR (95% CI)                                                 
  ---------------------- -------------------- ---------------------------------------------------------------- ------------------- ------------------- ------------------- -----------------------------------------
  Overall (N=4424)                                                                                                                                                         
  aLVM                   309/3807             8.92 (7.98--9.97)                                                1 (Reference)       1 (Reference)       1 (Reference)       1 (Reference)
  iLVM                   110/617              20.00 (16.59--24.11)                                             1.82 (1.46--2.28)   1.62 (1.30--2.03)   1.63 (1.30--2.04)   1.29 (0.98--1.70)
  Without LVH (N=3807)                                                                                                                                                     
  aLVM                   263/3559             8.13 (7.21--9.18)                                                1 (Reference)       1 (Reference)       1 (Reference)       [b](#jah34361-note-0009){ref-type="fn"}
  iLVM                   25/248               11.04 (7.46--16.34)                                              1.25 (0.82--1.88)   1.08 (0.71--1.64)   1.24 (0.81--1.89)   [b](#jah34361-note-0009){ref-type="fn"}
  With LVH (N=617)                                                                                                                                                         
  aLVM                   46/256               19.98 (14.96--26.67)                                             1 (Reference)       1 (Reference)       1 (Reference)       [b](#jah34361-note-0009){ref-type="fn"}
  iLVM                   85/361               26.26 (21.23--32.48)                                             1.28 (0.89--1.85)   1.17 (0.80--1.69)   1.26 (0.86--1.85)   [b](#jah34361-note-0009){ref-type="fn"}

Model 1: adjusted for age, sex, and body mass index. Model 2: adjusted for the variables in model 1 and diabetes mellitus, estimated glomerular filtration rate \<60 mL/min per 1.73 m^2^, education level (less than high school), current smoking, physical activity, and alcohol use (none, moderate, or heavy). Model 3: adjusted for the variables in model 2 and systolic blood pressure, diastolic blood pressure, and antihypertensive medication use. Model 4: adjusted for the variables in model 3 and LVH. The test for interaction between LVH and iLVM for all‐cause mortality had a *P* ~interaction~=0.664 (on model 4). aLVM indicates appropriate left ventricular mass; HR, hazard ratio; iLVM, inappropriate left ventricular mass; LVH, left ventricular hypertrophy.

Mortality rate per 1000 person‐years (95% CI).

Model 4 was not performed as these analyses are stratified by LVH status.

Discussion {#jah34361-sec-0019}
==========

In this community‐based cohort of blacks, 13.8% of participants had iLVM. iLVM was associated with an increased risk of CVD events. This association remained statistically significant after multivariable adjustment, including adjustment for LVH. When modeled as a continuous variable, progressively higher observed/predicted LVM ratio was also associated with an increased risk of CVD events. iLVM was not associated with the secondary outcome of all‐cause mortality.

Several studies have reported the prevalence of iLVM among whites and Asians. In these studies, the prevalence has ranged from 9% to 46%.[14](#jah34361-bib-0014){ref-type="ref"}, [28](#jah34361-bib-0028){ref-type="ref"}, [29](#jah34361-bib-0029){ref-type="ref"}, [30](#jah34361-bib-0030){ref-type="ref"}, [31](#jah34361-bib-0031){ref-type="ref"} In a study of 626 South African blacks, the prevalence of iLVM was 18.5%.[32](#jah34361-bib-0032){ref-type="ref"} However, there are few population‐based studies that have examined the prevalence of iLVM among blacks, a group who is at high risk for CVD events. In the current analysis of 4424 blacks in the JHS, the prevalence of iLVM was 13.8%.

Among participants without LVH, 6.5% had iLVM, whereas 58.5% of participants with LVH had iLVM. These data suggest that iLVM is not a subset or category within traditionally defined LVH.[14](#jah34361-bib-0014){ref-type="ref"}, [15](#jah34361-bib-0015){ref-type="ref"} In addition, although iLVM was not common among participants without LVH, it was associated with increased CVD risk in this group, suggesting it may provide meaningful additional prognostic information beyond traditionally defined LVH. LVH is a known risk factor for CVD events and all‐cause mortality, but it has important limitations.[1](#jah34361-bib-0001){ref-type="ref"} In particular, LVH is known to vary substantially between individuals on the basis of their race, sex, and the presence of other concomitant conditions.[1](#jah34361-bib-0001){ref-type="ref"} The observed/predicted LVM ratio may be useful when assessing the appropriateness of LVM accounting for characteristics, including cardiac workload or hemodynamic burden.

Prior studies that have examined the association between iLVM and CVD events have been conducted in clinic‐based settings among special populations of adults with prevalent hypertension,[8](#jah34361-bib-0008){ref-type="ref"}, [14](#jah34361-bib-0014){ref-type="ref"}, [33](#jah34361-bib-0033){ref-type="ref"}, [34](#jah34361-bib-0034){ref-type="ref"} chronic kidney disease,[35](#jah34361-bib-0035){ref-type="ref"} or diabetes mellitus.[36](#jah34361-bib-0036){ref-type="ref"} In the current community‐based study of blacks, iLVM was associated with \>2 times higher risk of CVD events over a median follow‐up of 9.7 years. In stratified analyses, the association between iLVM and CVD events was stronger among participants without LVH. These findings may suggest that iLVM may be useful as an additional marker of increased CVD risk, even among individuals without traditionally defined LVH.

Consistent with prior studies,[14](#jah34361-bib-0014){ref-type="ref"}, [15](#jah34361-bib-0015){ref-type="ref"} an observed/predicted LVM ratio \>95th percentile in a healthy JHS population was first calculated, and then used to define individuals as having iLVM. Among this cohort of blacks, the calculated cut point was 128.2%. More important, this value is similar to the cut point that has been calculated among separate, predominantly white cohorts (128%).[14](#jah34361-bib-0014){ref-type="ref"} Therefore, our findings both identify a threshold to define iLVM for a black cohort and also suggest that the same threshold to categorize excess LVM can appropriately be applied to multiple racial groups. The underlying mechanisms for iLVM are not understood. In the current analysis, compared with those with aLVM, individuals with iLVM were older, had a higher body mass index, and had a reduced eGFR, results consistent with prior studies.[8](#jah34361-bib-0008){ref-type="ref"}, [14](#jah34361-bib-0014){ref-type="ref"}, [28](#jah34361-bib-0028){ref-type="ref"}, [30](#jah34361-bib-0030){ref-type="ref"}, [31](#jah34361-bib-0031){ref-type="ref"}, [33](#jah34361-bib-0033){ref-type="ref"}, [37](#jah34361-bib-0037){ref-type="ref"}, [38](#jah34361-bib-0038){ref-type="ref"}, [39](#jah34361-bib-0039){ref-type="ref"} In addition, current smoking was more prevalent among those with iLVM. Although individuals with iLVM took more classes of antihypertensive medication and had a lower DBP, SBP was not higher among this group. Consequently, individuals with iLVM had a higher pulse pressure, primarily caused by a decrease in DBP, as opposed to an increase in SBP. There are baseline differences among participants with iLVM, including a higher prevalence of LVH, reduced ejection fraction, and concentric and eccentric hypertrophy.

It is unclear the extent to which iLVM is driven by changes in BP as iLVM has been associated with higher BP in some,[30](#jah34361-bib-0030){ref-type="ref"}, [31](#jah34361-bib-0031){ref-type="ref"} but not all, studies.[8](#jah34361-bib-0008){ref-type="ref"}, [28](#jah34361-bib-0028){ref-type="ref"}, [30](#jah34361-bib-0030){ref-type="ref"}, [37](#jah34361-bib-0037){ref-type="ref"}, [38](#jah34361-bib-0038){ref-type="ref"}, [39](#jah34361-bib-0039){ref-type="ref"} There are important hemodynamic and nonhemodynamic stimuli to left ventricular growth.[1](#jah34361-bib-0001){ref-type="ref"}, [29](#jah34361-bib-0029){ref-type="ref"}, [40](#jah34361-bib-0040){ref-type="ref"}, [41](#jah34361-bib-0041){ref-type="ref"}, [42](#jah34361-bib-0042){ref-type="ref"}, [43](#jah34361-bib-0043){ref-type="ref"} In response to hemodynamic stress is a cascade of cellular and biologic events that can result in the development of compensatory myocardial cell growth, including intracellular gene expression of proto‐oncogenes and the transcription of growth mediators, such as growth hormone and insulin‐like growth factor 1.[43](#jah34361-bib-0043){ref-type="ref"}, [44](#jah34361-bib-0044){ref-type="ref"}, [45](#jah34361-bib-0045){ref-type="ref"} However, prior studies have demonstrated that hemodynamic stress, such as elevated BP, may explain only a proportion of the variability of LVM.[1](#jah34361-bib-0001){ref-type="ref"} Nonhemodynamic stimuli, such as genetics, sex, and body size, may cause, or significantly modify, the effects of increased load and contribute to left ventricular growth.[42](#jah34361-bib-0042){ref-type="ref"}, [43](#jah34361-bib-0043){ref-type="ref"} It has been hypothesized that iLVM similarly reflects the interaction of genetic, neurohormonal, and biologic factors other than BP.[1](#jah34361-bib-0001){ref-type="ref"}, [29](#jah34361-bib-0029){ref-type="ref"}, [40](#jah34361-bib-0040){ref-type="ref"}, [41](#jah34361-bib-0041){ref-type="ref"} In understanding the mechanism behind why excess LVM is associated with an increased risk of CVD events, one explanation is that the biologic underpinnings of increases in LVM are also associated with high‐risk pathologic changes in body composition and chemistry, such as impaired glucose tolerance or metabolic syndrome.[46](#jah34361-bib-0046){ref-type="ref"}, [47](#jah34361-bib-0047){ref-type="ref"} Understanding the causes of and how to distinguish compensatory versus pathologic changes in cardiac remodeling remains a clinical challenge and an important area of research.

The current study has several strengths. We used data from the JHS, a community‐based cohort composed of blacks. This study represents one of the largest samples of blacks with echocardiographic data, and we were able to derive cut points for defining aLVM and iLVM in a healthy subgroup within the JHS and investigate the impact of iLVM among participants with and without LVH, separately. The current study used a common, validated method for calculating iLVM.[14](#jah34361-bib-0014){ref-type="ref"}, [28](#jah34361-bib-0028){ref-type="ref"}, [29](#jah34361-bib-0029){ref-type="ref"}, [30](#jah34361-bib-0030){ref-type="ref"}, [31](#jah34361-bib-0031){ref-type="ref"} Furthermore, the JHS actively identified CVD events and all‐cause mortality among participants, and events were adjudicated following a standardized protocol. However, there are several limitations to the current study. Calculating LVM by echocardiography requires geometric assumptions, including a fixed left ventricular shape of a prolate ellipsoid, which may not be applicable to some pathologic conditions.[20](#jah34361-bib-0020){ref-type="ref"} In addition, many of the components of the iLVM formula are dependent on reliable 2‐dimensional echocardiography, which may be subject to interobserver, and day‐to‐day, variability. This is partially overcome in the JHS cohort by using standardized protocols for obtaining and interpreting echocardiograms. Although echocardiography correlates well with cardiac magnetic resonance imaging, the gold standard and most precise way to assess LVM is cardiac magnetic resonance imaging, which does not require cardiac geometric assumptions.[48](#jah34361-bib-0048){ref-type="ref"}, [49](#jah34361-bib-0049){ref-type="ref"} Cardiac magnetic resonance imaging was not performed at the JHS baseline study visit and, therefore, cardiac magnetic resonance imaging results could not be used or correlated to echocardiographic findings in our analysis. Furthermore, echocardiograms were only obtained at the baseline study visit, and changes in iLVM status over time could not be evaluated. An additional limitation is that there were only a limited number of CVD events and deaths and the stratified analyses may have been underpowered to detect statistically significant associations. In addition, although iLVM was not a common phenotype among participants without LVH, it was associated with increased CVD risk in this group, suggesting it may provide meaningful additional prognostic information beyond traditional LVH, a finding that should be confirmed in future studies. Finally, consistent with prior studies, we adjusted for potential confounders in our models.[8](#jah34361-bib-0008){ref-type="ref"}, [14](#jah34361-bib-0014){ref-type="ref"}, [33](#jah34361-bib-0033){ref-type="ref"} However, it is possible that the associations between iLVM and CVD and all‐cause mortality are, in part, related to unidentified confounders that were not adjusted for in our multivariable analysis.

In conclusion, the prevalence of iLVM was high among blacks in the JHS. This phenotype, which is distinct from LVH, was associated with an increased risk of CVD events among participants without LVH. Also, iLVM was associated with an increased risk for all‐cause mortality. By accounting for multiple characteristics, including cardiac workload, sex, and body size, iLVM may provide an individualized approach to identify blacks at increased cardiovascular risk.
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